AMGEN Inc
NASDAQ: AMGN
$283.61
-$12.32 (-4.2%)
Closing Price on November 15, 2024
AMGN Articles
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
Published:
Last Updated:
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
Published:
Last Updated:
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher...
Published:
Last Updated:
Amgen reported better-than-expected fourth-quarter financial results after the markets closed Thursday.
Published:
Last Updated:
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Published:
Last Updated:
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Published:
Last Updated:
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Last Updated:
Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.
Published:
Last Updated:
Goldman Sachs has seen many top stocks offering great rewards for 2016. The reason may be different for each, but these are what the wealthiest and most sophisticated investors have been told to buy.
Published:
Last Updated:
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Published:
Last Updated:
Here are four stocks that, while expensive at current levels, have fundamentals good enough to continue and even exceed their success in 2015 through next year.
Published:
Last Updated:
Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better 2016 for this exciting sector?
Published:
Last Updated:
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
Published:
Last Updated: